as 05-17-2024 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Founded: | 2017 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 495.1M | IPO Year: | 2018 |
Target Price: | $14.84 | AVG Volume (30 days): | 2.3M |
Analyst Decision: | Buy | Number of Analysts: | 11 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.82 | EPS Growth: | N/A |
52 Week Low/High: | $2.23 - $6.41 | Next Earning Date: | 05-13-2024 |
Revenue: | $65,000 | Revenue Growth: | -48.00% |
Revenue Growth (this year): | -56.7% | Revenue Growth (next year): | 16748.74% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Jan 30 '24 | Buy | $3.60 | 190 | $683.05 | 819,590 | SEC Form 4 |
MESSEMER DEBORAH M. | ALLO | Director | Dec 18 '23 | Sell | $2.70 | 18,640 | $50,316.82 | 62,456 | SEC Form 4 |
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Zacks
5 days ago
MT Newswires
5 days ago
MT Newswires
5 days ago
GuruFocus.com
6 days ago
MT Newswires
6 days ago
Zacks
6 days ago
GlobeNewswire
6 days ago